Stemtech Corp (STEK) Cash & Equivalents (2012 - 2026)

Stemtech has reported Cash & Equivalents for 15 years, with the latest figure at $256149.0 in Q1 2026.

• Quarterly Cash & Equivalents fell 16.25% year-over-year to $256149.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $256149.0 (down 16.25% YoY) and the FY2025 annual result came in at $238245.0, down 6.68% from the prior year.
• Cash & Equivalents climbed to $256149.0 in Q1 2026 per STEK's latest filing, from $238245.0 in the prior quarter.
• Over five years, Cash & Equivalents peaked at $511201.0 in Q1 2022 and troughed at $114166.0 in Q4 2023.
• A 5-year average of $271058.8 and a median of $259570.0 in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents plunged 92.3% in 2022, then jumped 162.93% in 2023.
• Over 5 years, Cash & Equivalents stood at $132487.0 in 2022, then dropped by 13.83% to $114166.0 in 2023, then soared by 123.62% to $255298.0 in 2024, then declined by 6.68% to $238245.0 in 2025, then grew by 7.51% to $256149.0 in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $256149.0, $238245.0, and $255416.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.